Bilateral versus single internal thoracic coronary artery bypass grafting: the ART RCT

Author:

Flather Marcus1ORCID,Dimagli Arnaldo2ORCID,Benedetto Umberto2ORCID,Lees Belinda3ORCID,Gray Alastair4ORCID,Gerry Stephen5ORCID,Naik Ajita6ORCID,Cook Jo7ORCID,Gaudino Mario6ORCID,Little Matthew4ORCID,Taggart David P3ORCID

Affiliation:

1. Norwich Medical School, University of East Anglia and Norfolk and Norwich University Hospital, Norwich, UK

2. School of Clinical Sciences, University of Bristol and Bristol Royal Infirmary, Bristol, UK

3. Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Oxford, UK

4. Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK

5. Centre for Statistics in Medicine, Botnar Research Centre, University of Oxford, Oxford, UK

6. Department of Cardiothoracic Surgery Weill Cornell Medicine New York – Presbyterian Hospital, New York, USA

7. Surgical Intervention Trials Unit, Botnar Research Centre, University of Oxford, Oxford, UK

Abstract

Background There is debate whether the use of more arterial grafts during coronary artery bypass graft surgery provides advantages to the standard operation using the left internal thoracic artery plus vein grafts. We review data from the Arterial Revascularisation Trial to determine whether there is support for the multiple arterial graft hypothesis. Methods Patients undergoing coronary artery bypass graft for clinical reasons and who provided written informed consent were randomised to standard coronary artery bypass graft using the single internal thoracic artery or use of bilateral internal thoracic arteries. Additional vein grafts could be used. The primary outcome was all-cause mortality at 10 years and exploratory analyses were carried out to test the multiple arterial graft hypothesis. Results A total of 3102 patients were enrolled (1548 bilateral internal thoracic artery and 1554 single internal thoracic artery). Follow-up to 10 years for vital status was 98% complete. In the bilateral group, 14% of patients received a single internal thoracic artery only and use of radial artery grafts occurred in about 20% of patients in both groups. Aspirin was used in 81% of the patients, beta-blockers in 74%, statins in 90% and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in 73%. At 10 years, death rates were 20.3% and 21.2% in the bilateral internal thoracic artery and single internal thoracic artery groups, respectively (hazard ratio 0.96, 95% confidence intervals 0.82 to 1.12; p = 0.62) and composite of all-cause mortality, myocardial infarction or stroke 24.9% and 27.3%, respectively (hazard ratio 0.90, 95% confidence interval 0.79 to 1.03; p = 0.12). Exploratory analyses using the ‘as-treated’ approach indicate that outcomes were better in patients who received multiple arterial grafts (adding the right internal thoracic and/or radial arteries) compared with a single arterial graft. This effect appeared to be greater in patients with diabetes and those aged 70 years or less. Use of total arterial grafting without vein grafts may provide the best outcomes. Limitations The elevated cross-over rate between bilateral internal thoracic artery and single internal thoracic artery and the non-randomised use of radial artery grafts may have contributed to a loss of power to detect a difference in mortality between the two groups. Moreover, secondary analyses are prone to bias as they compare non-randomised groups. Conclusions The Arterial Revascularisation Trial is one of the largest long-term studies in cardiac surgery. The primary analysis did not show a mortality benefit for bilateral internal thoracic artery at 10 years, perhaps due to high crossover rates in the bilateral internal thoracic artery group and concomitant use of the radial artery. Secondary analyses suggest a mortality benefit for patients receiving multiple arterial grafts compared with single arterial graft with possible greater effects in patients with diabetes and separately in patients aged 70 years or above. The trial will follow patients to 15 years and the continuing Randomized Comparison of the Clinical Outcome of Single versus Multiple Arterial Grafts trial will further test the multiple arterial graft hypothesis. Trial registration This trial is registered as ISRCTN46552265. Funding This project was funded by the British Heart Foundation, the UK. Medical Research Council and the National Institute for Health and Care Research (NIHR) Efficacy and Mechanism Evaluation programme and will be published in full in Efficacy and Mechanism Evaluation; Vol. 10, No. 7. See the NIHR Journals Library website for further project information.

Funder

Efficacy and Mechanism Evaluation programme

Publisher

National Institute for Health and Care Research

Reference47 articles.

1. European Society of Cardiology: cardiovascular disease statistics 2021;Timmis;Eur Heart J,2022

2. 2018 ESC/EACTS Guidelines on myocardial revascularization;Neumann;Eur Heart J,2019

3. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines;Lawton;Circulation,2022

4. Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events;Loop;N Engl J Med,1986

5. Fifteen- to twenty-one-year angiographic assessment of internal thoracic artery as a bypass conduit;Barner;Ann Thorac Surg,1994

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3